Vancouver, Canada – October 17, 2025 – Augurex Life Sciences, a leader in autoimmune biomarker-based diagnostics, today announced that it will be exhibiting at Booth 919 and presenting new data at the American College of Rheumatology (ACR) Convergence 2025, taking place October 24–29 in Chicago, Illinois.
Augurex’s new research highlights the diagnostic value of Anti-14-3-3eta Multiplex (14-3-3eta autoantibodies) for the detection of axial spondyloarthritis (axSpA). Findings from these studies demonstrate the clinical potential of anti-14-3-3eta autoantibodies as a novel biomarker that supports earlier and more accurate identification of inflammatory back pain and improves differentiation from mechanical causes.
Scientific Presentations at ACR 2025
Oral Presentation Details:
- Title: Autoantibodies to 14-3-3 eta: A Novel Diagnostic Biomarker for Axial Spondyloarthritis
- Authors: Raj Sengupta, Anthony Marotta, Walter P. Maksymowych, Charlotte Cavill, Stephen Bleakley and Norma Biln,
- Abstract Number: 2636
- Session Name: Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes II: Advances in Axial Spondyloarthritis (2633–2638)
- Session Date/Time: Tuesday, October 28, 2025; 3:00 p.m. – 4:30 p.m. Central Time
- Presentation Time: 3:45 p.m. – 4:00 p.m. Central Time
- Location: Room W183A-C
Poster Presentation Details:
- Title: Evaluating the Diagnostic Utility of 14-3-3eta Autoantibodies in Axial Spondyloarthritis: A Multiplex Assay Approach
- Authors: Anthony Marotta, Walter P. Maksymowych, Stephen Bleakley, Stephanie Wichuk and Norma Biln
- Abstract Number: 0531
- Session Name: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I (0522–0553)
- Session Date/Time: Sunday, October 26, 2025; 10:30 a.m. -12:30 p.m. Central Time
- Location: Poster Hall F1
- Title: The 14-3-3 eta AAb biomarker improves discriminative performance of CRP and HLA-B27 to differentiate people with radiographic axSpA from those with mechanical back pain
- Authors: Walter P. Maksymowych, Raj Sengupta, Anthony Marotta, Stephanie Wichuk, Charlotte Cavill, Stephen Bleakley and Norma Biln
- Abstract Number: 2335
- Session Name: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III (2305–2337)
- Session Date/Time: Tuesday, October 28, 2025; 10:30 a.m. – 12:30 p.m. Central Time
- Location: Poster Hall F1
In addition to the presentations, Augurex will showcase its biomarker-based diagnostic portfolio at Booth 919, featuring:
- JOINTstat® | 14-3-3eta: A diagnostic and monitoring biomarker that supports early detection and management of rheumatoid arthritis (RA).
- SPINEstat® | Anti-14-3-3eta Multiplex: A first-in-class diagnostic test for the early and accurate detection of axSpA.
Augurex looks forward to connecting with rheumatology professionals, clinicians, and researchers at ACR Convergence 2025 to share how its innovations are advancing biomarker-driven solutions that support earlier diagnosis and improved patient outcomes.
For more information or to connect with the Augurex team during the conference, visit Booth 919 or contact info@augurex.com.
About Augurex
Augurex is a commercial-stage diagnostics company dedicated to the early identification and diagnosis of autoimmune disorders, allowing treatment options to be optimized and personalized for patients around the world. Augurex’s lead diagnostic test, which detects the 14-3-3eta protein, is available as JOINTstat® in Canada and Great Britain, and is an important tool in the diagnosis and management of inflammatory diseases, including rheumatoid arthritis. The analyte-specific reagents to detect 14-3-3eta are available for purchase and use by U.S. clinical laboratories as a component of diagnostic tests developed by such laboratories. The Anti-14-3-3eta Multiplex ASRs, available as SPINEstat® in Canada and Great Britain, expands Augurex’s biomarker-informed diagnostic autoimmune solutions into axial spondyloarthritis, an autoimmune disease often misdiagnosed as low back pain, and which, if untreated, can lead to impaired spinal mobility and fusion of the vertebrae. Learn more about Augurex at www.augurex.com and follow us on Facebook, LinkedIn, and X.
Media Contact
Nima Mazinani
(604) 674-8231
media@augurex.com